-
Choline kinase α2 acts as a protein kinase to promote the lipolysis of lipid droplets
Time of Update: 2023-02-03
Study results Finally, the authors conducted experiments on cell biology and nude mice and found that the cytostatic effect induced by PLIN2/3 phosphorylation defects is the result of lipolysis and decreased fatty acid production, rather than lipid accumulation.
-
Nature Medicine: MSKCC Releases Blockbuster Results of Liquid Biopsy for Lung Cancer! Large international cohorts confirmed that ctDNA is effective in predicting non-trivial prognosis and guiding
Time of Update: 2022-11-26
[4] [5] In recent years, the treatment and prognosis of patients with non-small cell lung cancer (NSCLC) have greatly improved thanks to targeted therapy, which is mainly based on the wide application of tissue sequencing, but in the real world, there are many patients who cannot perform tissue sequencing for various reasons [1-3], so it is easier to obtain samples and detect blood circulating tumor DNA (ctDNA) "homeopathic".
-
Cell Rep: A novel mechanism by which copper ions regulate fatty acid metabolism
Time of Update: 2022-10-25
These experiments proved that only SCO1, loaded with copper ions, can effectively form complexes with AMPKa and LKB1 and promote AMPK activation and upregulation of fatty acid oxidation.
-
New "universal" COVID-19 treatments
Time of Update: 2022-10-25
Gaurav Sahay and his collaborators at Oregon State University and the Texas Biomedical Research Institute demonstrated in a mouse model that it is possible to prompt the production of a protein that can block multiple variants of the SARS-CoV-2 virus from entering cells and causing respiratory disease.
-
PNAS: a new strategy to inhibit the growth of prostate cancer
Time of Update: 2022-10-25
essayA COP1-GATA2 axis suppresses AR signaling and prostate cancer The search for valuable interventions for prostate cancer treatment has guided research in Dr. Yang Feng's lab at Baylor College of Medicine.
-
Nature sub-journal: Gene 'Achilles heel' found in ovarian and uterine cancers
Time of Update: 2022-10-16
Disrupting phosphate transport in cancer cells, such as with a protein they used to disable XPR1 in their experiments, could be an effective therapeutic strategy, the team added .
-
The tertiary prevention of liver cancer, look at the guidelines for the integrated diagnosis and treatment of liver cancer in China
Time of Update: 2022-10-03
The "Guidelines for the Integrated Diagnosis and Treatment of Tumors in China (CACA) - Liver Cancer Section" involves the epidemiology, screening, imaging examination, pathological assessment of liver cancer, as well as multidisciplinary integrated treatment methods such as surgical treatment, interventional therapy, systematic drug therapy, radiotherapy and traditional Chinese medicine treatment, taking into account the whole process of rehabilitation management.
-
Hepatic treatment of intestinal disease: Xie Cen/He Shijun et al. discovered the molecular mechanism of liver bile acid metabolism affecting intestinal barrier function
Time of Update: 2022-09-15
The study found that the liver bile acid metabolism enzyme CYP8B1 remotely inhibits the self-renewal of crypt-based intestinal stem cells (ISCs) through its product bile acid (CA), preventing intestinal epithelial barrier repair and aggravating the inflammatory response.
-
Nature Sub-Journal: A Breakthrough in Cell Engineering! High-yielding CRISPR without viral vectors
Time of Update: 2022-09-09
"We demonstrated that we can design more than 1 billion cells in a single run, which is far more than the number of cells we need to treat a single patient," said first author Brian Shy. From double-stranded to single-stranded DNA CRISPR-Cas9, a system for editing genes within living cells, has been used as a basic research tool for the past decade.
-
BJH: Daratumumab, lenalidomide, and dexamethasone in newly diagnosed patients with systemic light chain amyloidosis associated with multiple myeloma
Time of Update: 2022-08-12
In this retrospective cohort study, we analyzed 6-month hematologic and organ responses to daratumumab, lenalidomide, and dexamethasone (DRd), a newly diagnosed transplant-ineligible MM patient standard of care in 3 patients with MM with systemic AL amyloidosis at diagnosis .
-
Regeneron acquires Checkmate for $250M, collaborates with SpringWorks on multiple myeloma therapy
Time of Update: 2022-06-07
A few days ago, Regeneron announced the acquisition of Checkmate Pharmaceuticals, and also said that it will cooperate with SpringWorks Therapeutics on a clinical trial to jointly evaluate the efficacy of Regeneron REGN5458 in combination with SpringWorks drug nirogacestat in patients with multiple myeloma .
-
Proton Bio and Biopharma Announce Strategic Cooperation to Accelerate the Development of Solid Tumor Cell Therapy Drugs
Time of Update: 2022-06-05
Hu Pingsheng, founder of Shengnuo Pharmaceutical, said : "The strategic cooperation between Shengnuo Pharmaceutical and Proton Bio will promote the development of new solid tumor immune cell drugs and accelerate the clinical research of a series of pipelines.
-
JCI: Uncovering novel molecular mechanisms of the body's defense against cancer progression
Time of Update: 2022-05-23
Recently, in a research report titled "LC3-associated phagocytosis in bone marrow macrophages suppresses acute myeloid leukemia progression through STING activation" published in the international journal Journal of Clinical Investigation, scientists from the University of East Anglia and other institutions through research Uncovering how the body's immune system is induced to attack cancer cells could lead to new treatments for leukemia patients .
-
European Radiology: In non-small cell lung cancer patients, we found another strong imaging prognostic marker
Time of Update: 2022-05-21
Recently, a study published in the journal European Radiology explored two new geometric variables, the normalized SUVpeak-to-centre distance (nSCD) and the normalized SUVmax obtained from pre-treatment [ 18 F]FDG PET/CT Prognostic value of distance to periphery (nSPD) and its correlation with classical metabolic parameters in NSCLC patients undergoing surgery .
-
WuXi Junuo CAR-T product clinical application for new indications was approved
Time of Update: 2022-05-18
On April 20, WuXi Junuo announced that the clinical trial application of Ruikiolanza injection for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) has been approved.
